Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration

Oncogene volume 29, pages 3010–3016 (2010)Cite this article

Subjects

Abstract

Deleted in liver cancer 1 (DLC1) is a RhoGTPase activation protein-containing tumor suppressor that associates with various types of cancer. Although DLC2 shares a similar domain structure with that of DLC1, the function of DLC2 is not well characterized. Here, we describe the expression and ablation of DLC2 in mice using a reporter-knockout approach. DLC2 is expressed in several tissues and in endothelial cells (ECs) of blood vessels. Although ECs and blood vessels show no histological abnormalities and mice appear overall healthy, DLC2-mutant mice display enhanced angiogenic responses induced by matrigel and by tumor cells. Silencing of DLC2 in human ECs has reduced cell attachment, increased migration, and tube formation. These changes are rescued by silencing of RhoA, suggesting that the process is RhoA pathway dependent. These results indicate that DLC2 is not required for mouse development and normal vessel formation, but may protect mouse from unwanted angiogenesis induced by, for example, tumor cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY et al. (2003). Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 278: 10824–10830.

    Article  CAS  PubMed  Google Scholar 

  • Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC . (2005). DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 579: 1191–1196.

    Article  CAS  PubMed  Google Scholar 

  • Durkin ME, Ullmannova V, Guan M, Popescu NC . (2007a). Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene 26: 4580–4589.

    Article  CAS  PubMed  Google Scholar 

  • Durkin ME, Yuan BZ, Thorgeirsson SS, Popescu NC . (2002). Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene 288: 119–127.

    Article  CAS  PubMed  Google Scholar 

  • Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS et al. (2007b). DLC-1: a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 11: 1185–1207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY et al. (2005). Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 102: 15207–15212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liao YC, Lo SH . (2008). Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 40: 843–847.

    Article  CAS  PubMed  Google Scholar 

  • Liao YC, Shih YP, Lo SH . (2008). Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res 68: 7718–7722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liao YC, Si L, Devere White RW, Lo SH . (2007). The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 176: 43–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C et al. (2005). Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 19: 234–236.

    Article  CAS  PubMed  Google Scholar 

  • Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R et al. (2007). Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 104: 9012–9017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, Zhang Y et al. (2004). A reliable lacZ expression reporter cassette for multipurpose, knockout-first alleles. Genesis 38: 151–158.

    Article  CAS  PubMed  Google Scholar 

  • Ullmannova V, Popescu NC . (2006). Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 29: 1127–1132.

    CAS  PubMed  Google Scholar 

  • Xiaorong L, Wei W, Liyuan Q, Kaiyan Y . (2008). Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer 8: 205.

    Article  PubMed  PubMed Central  Google Scholar 

  • Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C et al. (2008). DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 22: 1439–1444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yau TO, Leung TH, Lam S, Cheung OF, Tung EK, Khong PL et al. (2009). Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS One 4: e6566.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC . (1998). Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 58: 2196–2199.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Knockout Mouse Project Repository for DLC2 ES cells. This work is supported in part by grants from the National Institutes of Health (CA102537) to SHL.

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Medicine University of California-Davis, Sacramento, CA, USA

    Y Lin, N-T Chen, Y-P Shih, Y-C Liao & S H Lo

  2. Department of Pathology, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China

    Y Lin & L Xue

Authors
  1. Y Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N-T Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y-P Shih
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y-C Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S H Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S H Lo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, Y., Chen, NT., Shih, YP. et al. DLC2 modulates angiogenic responses in vascular endothelial cells by regulating cell attachment and migration. Oncogene 29, 3010–3016 (2010). https://doi.org/10.1038/onc.2010.54

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.54

Keywords

This article is cited by

Search

Advanced search

Quick links